Stock Fundamentals

Company Information

Company Name
Verastem Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US92337C2035
CIK: 0001526119
CUSIP: 92337C104
Currency: USD
Full Time Employees: 102
Phone: 781 292 4200
Fiscal Year End: December
IPO Date: Jan 27, 2012
Description:

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS, which in Phase 1/2 trial entitled RAMP 203; VS-7375, and VS-7375-101 is a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers; and AVMAPKI, FAKZYNJA, CO-PACK, is an avutometinib capsules, and defactinib tablets. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.

Address:

117 Kendrick Street, Needham, MA, United States, 02494

Directors & Officers

Name Title Year Born
Mr. Daniel W. Paterson President, CEO & Director 1961
Mr. Daniel Calkins Chief Financial Officer 1988
Dr. Michael Glen Kauffman M.D., Ph.D. President of Development & Director 1963
Dr. Robert A. Weinberg Ph.D. Co-Founder & Chair of Scientific Advisory Board NA
Dr. Michelle Detwiler M.D., Ph.D. Co-Founder 1976
Ms. Lori Horvat Executive Vice President of Portfolio Strategy & Operations NA
Dr. Jonathan Pachter Ph.D. Chief Scientific Officer 1958
Ms. Julissa Viana Vice President of Corporate Communications & Investor Relations NA
Mr. Mark J. Wanda Senior VP of Legal & Chief Compliance Officer NA
Ms. Cathy Carew Chief Organizational Effectiveness Officer NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Feb 04, 2026 Dan Paterson N/A Sale 970.00 $6.69 $6.49K
Jan 12, 2026 Dan Paterson N/A Sale 10.32K $7.16 $73.90K
Jan 12, 2026 Daniel Calkins N/A Sale 5.04K $7.16 $36.08K
Dec 24, 2025 Daniel Calkins N/A Sale 80.00 $7.86 $628.80
Dec 16, 2025 Brian M Stuglik N/A Sale 592.00 $9.14 $5.41K
Dec 16, 2025 Dan Paterson N/A Sale 393.00 $9.14 $3.59K
Dec 16, 2025 Robert E Gagnon N/A Sale 283.00 $9.14 $2.59K
Dec 10, 2025 Dan Paterson N/A Sale 2.00K $10.07 $20.14K
Dec 08, 2025 Dan Paterson N/A Sale 2.00K $10.50 $21.00K
Dec 05, 2025 Dan Paterson N/A Sale 2.00K $10.61 $21.22K
Dec 03, 2025 Dan Paterson N/A Sale 2.00K $10.00 $20.00K
Dec 01, 2025 Dan Paterson N/A Sale 2.00K $10.39 $20.78K
Nov 28, 2025 Dan Paterson N/A Sale 2.00K $10.79 $21.58K
Nov 26, 2025 Dan Paterson N/A Sale 2.00K $10.32 $20.64K
Nov 24, 2025 Dan Paterson N/A Sale 2.00K $10.00 $20.00K
Nov 21, 2025 Paul A Bunn N/A Sale 6.25K $10.00 $62.50K
Nov 21, 2025 Dan Paterson N/A Sale 2.00K $10.00 $20.00K
Nov 21, 2025 Michael Kauffman N/A Sale 8.55K $10.00 $85.50K
Nov 03, 2025 Dan Paterson N/A Sale 3.30K $9.74 $32.13K
Oct 09, 2025 Paul A Bunn N/A Sale 8.33K $9.06 $75.50K

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
RTW INVESTMENTS, LLC 6.58M Mar 31, 2026 7.49% $0.35 0.00%
BlackRock Inc 6.19M Mar 31, 2026 7.05% $0.00 30.34%
Deep Track Capital, LP 5.74M Mar 31, 2026 6.54% $0.50 0.00%
Armistice Capital, LLC 4.59M Mar 31, 2026 5.23% $0.43 29.86%
Vanguard Group Inc 4.15M Dec 31, 2025 4.73% $0.00 19.36%
Nantahala Capital Management, LLC 3.58M Mar 31, 2026 4.08% $0.70 675.70%
State Street Corp 3.52M Mar 31, 2026 4.00% $0.00 9.24%
Stonepine Capital Management Llc 3.30M Mar 31, 2026 3.76% $7.01 20.87%
Foresite Capital Management VI LLC 3.15M Mar 31, 2026 3.58% $3.62 0.37%
Millennium Management LLC 2.41M Mar 31, 2026 2.75% $0.01 334.49%
Citadel Advisors Llc 2.31M Mar 31, 2026 2.63% $0.00 -1.90%
Morgan Stanley - Brokerage Accounts 2.25M Mar 31, 2026 2.56% $0.00 20.07%
Rosalind Advisors, Inc. 2.14M Mar 31, 2026 2.43% $4.55 19.57%
Alyeska Investment Group, L.P. 2.05M Mar 31, 2026 2.33% $0.03 0.00%
AIGH Capital Management, LLC 2.00M Mar 31, 2026 2.28% $1.45 0.00%
Geode Capital Management, LLC 1.72M Mar 31, 2026 1.96% $0.00 23.31%
J. Goldman & Co LP 1.68M Mar 31, 2026 1.91% $0.26 77.43%
The Goldman Sachs Group Inc 1.48M Mar 31, 2026 1.69% $0.00 -0.76%
Qube Research & Technologies 1.48M Mar 31, 2026 1.68% $0.01 479.06%
NEXTBio Capital Management LP 1.31M Mar 31, 2026 1.49% $3.22 -0.04%

Shares Statistics

Shares Outstanding: 87.87M
Shares Float: 70.40M
% Insiders: 95.40%
% Institutions: 9,356.50%
Short % Float: 20.46%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard Total Stock Mkt Idx Inv 2.42M 2.76% ▲ 0.00% Apr 30, 2026
2 State Street® SPDR® S&P® Biotech ETF 2.30M 2.62% ▼ 0.70% Apr 30, 2026
3 iShares Russell 2000 ETF 1.55M 1.76% ▲ 0.85% Apr 30, 2026
4 Vanguard Institutional Extnd Mkt Idx Tr 825.98K 0.94% ▲ 0.62% Apr 30, 2026
5 Franklin Biotechnology Discv A(acc)USD 703.22K 0.80% ▲ 0.00% Apr 30, 2026
6 BlackRock Advantage Small Cap Core Instl 701.34K 0.80% ▲ 181.81% Apr 30, 2026
7 Fidelity Small Cap Index 523.20K 0.60% ▲ 1.07% Feb 28, 2026
8 MEDICAL BioHealth EUR Acc 520.17K 0.59% ▼ 0.10% Mar 31, 2026
9 Fidelity Enhanced Small Cap Core ETF 435.64K 0.50% ▼ 1.15% Apr 30, 2026
10 Franklin Biotechnology Discovery A 401.74K 0.46% ▲ 0.00% Apr 30, 2026

Valuation Metrics

Enterprise Value: $272.87M
Trailing P/E: 0.00
Forward P/E: 0.00

Financial Highlights

Market Cap: $334.80M
EBITDA: $-169.86M
PEG Ratio: $-1.89
Book Value: $0.74
Earnings/Share: $-2.52
Profit Margin: 0.00%
Operating Margin: -240.46%
ROA (TTM): -59.41%
ROE (TTM): -786.15%
Revenue (TTM): $49.59M
Revenue/Share (TTM): $0.62
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -78.60%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 3.09x 1.43x 0.77x -149.50x -0.48x
2024-12-31 3.07x -1.44x 1.28x -25.20x -0.33x
2023-12-31 5.45x 0.72x 0.62x -22.25x -0.49x
2022-12-31 4.29x 0.54x 0.50x -34.13x -0.36x
2021-12-31 5.69x 0.01x 0.19x -6.16x -0.01x
2020-12-31 8.48x 0.17x 0.25x -3.13x -0.39x
2019-12-31 2.84x 14.50x 0.95x -6.42x -0.82x
2018-12-31 6.83x 0.97x 0.55x -16.31x -1.85x
2017-12-31 5.13x 0.51x 0.36x -121.30x -0.44x
2016-12-31 7.40x 0.00x 0.14x N/A 0.00x
2015-12-31 10.96x 0.00x 0.09x N/A 0.00x
2014-12-31 10.36x 0.00x 0.10x N/A 0.00x
2013-12-31 13.06x 0.00x 0.06x N/A 0.00x
2012-12-31 23.79x 0.00x 0.03x N/A 0.00x
2011-12-31 15.24x 0.00x 1.22x N/A 0.00x
2010-12-31 0.00x 0.00x 0.10x N/A 0.00x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about VSTM.US!